Evaluation of lipid profile, macular toxicity and clinical manifestations according to APO E genotype in systemic lupus erythematosus and rheumatoid arthritis patients treated with chloroquine

被引:4
作者
Mercado, MVD
Muñoz-Valle, JF
Santos, A
Bernard-Medina, AG
Martínez-Bonilla, G
Paczka, JA
Ruiz-García, H
Orozco-Alcala, J
Orozco-Barocio, G
Quezada-Arellano, D
Gurrola-Díaz, C
Nuño-González, P
Best-Aguilera, CR
Chávez-Castellanos, R
Panduro, A
机构
[1] OPD Antiguo Hosp Civil Guadalajara, Inst Biol Mol Med, CUCS, UG, Guadalajara 44280, Jalisco, Mexico
[2] OPD Antiguo Hosp Civil Guadalajara, Serv Reumatol, Guadalajara 44280, Jalisco, Mexico
[3] Hosp Gen Occidente Seguro Social, SSJ, Jalisco, Mexico
关键词
apolipoprotein E; chloroquine; dyslipidemia; rheumatoid arthritis; systemic lupus erythematosus;
D O I
10.1080/030097402317255345
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To investigate the effect of APO E gene polymorphism over lipid profile, macular toxicity and clinical manifestations in RA and SEE patients treated with chloroquine. Materials and methods: We studied 45 RA and 29 SLE patients treated with chloroquine who were classified based on the therapeutic regime of chloroquine into three groups: A) Cumulative dose of 100-300g, B) > 300g and C) Never received chloroquine. Clinical evaluation, fasting lipid profile. visual field testing and stereoscopic photos of the retina were performed. APO E genotype was determined by PCR-RFLP. Results: Reduced apo B levels in RA and SLE according to the cumulative dose of chloroquine 2.3 APO E genotype in a subset of SEE patients were observed. Macular toxicity was independent of both APO E genotype and cumulative chloroquine dose. Conclusions: Reduced apo B levels were observed associated to chloroquine treatment and 2.3 APO E genotype.
引用
收藏
页码:32 / 37
页数:6
相关论文
共 34 条
[1]   THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].
ARNETT, FC ;
EDWORTHY, SM ;
BLOCH, DA ;
MCSHANE, DJ ;
FRIES, JF ;
COOPER, NS ;
HEALEY, LA ;
KAPLAN, SR ;
LIANG, MH ;
LUTHRA, HS ;
MEDSGER, TA ;
MITCHELL, DM ;
NEUSTADT, DH ;
PINALS, RS ;
SCHALLER, JG ;
SHARP, JT ;
WILDER, RL ;
HUNDER, GG .
ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324
[2]  
Asanuma Y, 1999, ARTHRITIS RHEUM, V42, P443, DOI 10.1002/1529-0131(199904)42:3<443::AID-ANR8>3.0.CO
[3]  
2-Q
[4]  
BASU SK, 1982, J BIOL CHEM, V257, P9788
[5]  
Beattie C, 1997, J RHEUMATOL, V24, P1393
[6]  
BERNSTEIN HN, 1991, ANN OPHTHALMOL, V23, P292
[7]   APOLIPOPROTEIN-E SYNTHESIS IN HUMAN-KIDNEY, ADRENAL-GLAND, AND LIVER [J].
BLUE, ML ;
WILLIAMS, DL ;
ZUCKER, S ;
KHAN, SA ;
BLUM, CB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1983, 80 (01) :283-287
[8]  
DALLINGATHIE GM, 1995, CLIN CHEM, V41, P73
[9]  
DAS HK, 1985, J BIOL CHEM, V260, P6240
[10]   APOLIPOPROTEIN-E POLYMORPHISM AND ATHEROSCLEROSIS [J].
DAVIGNON, J ;
GREGG, RE ;
SING, CF .
ARTERIOSCLEROSIS, 1988, 8 (01) :1-21